Omega Therapeutics Announces Jennifer Nelson, Ph.D., as Senior Vice President of Research
August 14, 2024 07:00 ET
|
Omega Therapeutics
CAMBRIDGE, Mass., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a biotechnology company pioneering the development of a new class of programmable epigenomic...
Omega Therapeutics Reports Second Quarter 2024 Financial Results and Highlights Recent Company Progress
August 06, 2024 07:00 ET
|
Omega Therapeutics
Advanced MYCHELANGELO™ I trial; Company expects to select recommended dose for expansion and initiate monotherapy and combination expansion cohorts in fourth quarter of 2024Reinforced diverse...
Omega Therapeutics Announces Election of Richard N. Kender to Board of Directors
June 24, 2024 07:00 ET
|
Omega Therapeutics
CAMBRIDGE, Mass., June 24, 2024 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the development of a new class of...
Omega Therapeutics To Participate In Two Upcoming Investor Conferences
May 30, 2024 07:00 ET
|
Omega Therapeutics
CAMBRIDGE, Mass., May 30, 2024 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the development of a new class of programmable...
Omega Therapeutics Appoints Kaan Certel, Ph.D., as Chief Business Officer
May 29, 2024 07:00 ET
|
Omega Therapeutics
CAMBRIDGE, Mass., May 29, 2024 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the development of a new class of programmable...
Omega Therapeutics Presents New Preclinical Data at ASGCT 2024 Demonstrating Tunable and Durable Upregulation of Gene Expression with Epigenomic Controllers
May 08, 2024 07:00 ET
|
Omega Therapeutics
Programmable epigenomic mRNA candidates enabled durable and robust upregulation of gene expression across a diverse set of gene types and regulatory mechanismsAdditional OMEGA platform capabilities...
Omega Therapeutics Reports First Quarter 2024 Financial Results and Highlights Recent Company Progress
May 06, 2024 07:00 ET
|
Omega Therapeutics
Advanced MYCHELANGELO™ I trial dose escalation to Cohort 5; Presentation of additional monotherapy data and planned expansion into Phase 2 settings expected in mid-2024Presented new preclinical data...
Omega Therapeutics to Present New Preclinical Data on Epigenomic Upregulation at the American Society of Gene and Cell Therapy 27th Annual Meeting
April 23, 2024 07:00 ET
|
Omega Therapeutics
CAMBRIDGE, Mass., April 23, 2024 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the development of a new class of...
Omega Therapeutics Presents New Preclinical Data at AACR 2024 Supporting the Potential of Precision Epigenomic Control
April 09, 2024 07:00 ET
|
Omega Therapeutics
MYC-directed epigenomic controller exerts anti-tumor effect in preclinical models of EGFR inhibitor-resistant NSCLC regardless of underlying resistance mechanismValidation of novel translational assay...
Omega Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Strategic Update
March 28, 2024 09:15 ET
|
Omega Therapeutics
Advanced OTX-2002 in MYCHELANGELO™ I trial; initial cohorts demonstrated encouraging disease control rate in late-stage HCC patientsEstablished a research collaboration with Novo Nordisk to develop an...